NewsNTech
The evidentiary floor for pediatric gender medicine is a live question in federal policy.
England's National Health Service paused cross-sex hormones for patients aged 16 and 17 after finding the supporting research "really weak," and a prior ban covering children under 16 was already in place.
At a Friday rally at Michigan State University, Michigan Democratic U.S.
Senate candidate Abdul El-Sayed argued that treatment decisions of this kind belong between patients and their providers, with no government role in the clinical room.
Keep reading